Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence
暂无分享,去创建一个
Hideo Negishi | Kohzoh Imai | Kenya Honda | K. Honda | T. Taniguchi | A. Takaoka | T. Shibue | K. Imai | H. Yanai | S. Sasaki | S. Hayakawa | Shigeru Sasaki | Tadatsugu Taniguchi | Akinori Takaoka | Tsukasa Shibue | Hideyuki Yanai | Dagmar Stoiber | Sumio Hayakawa | Hideaki Kikuchi | D. Stoiber | H. Kikuchi | Hideo Negishi
[1] K. Kinzler,et al. Genetic determinants of p53-induced apoptosis and growth arrest. , 1996, Genes & development.
[2] G. Matlashewski,et al. Control of interferon signaling in human papillomavirus infection. , 2001, Cytokine & growth factor reviews.
[3] C. Biron. Interferons α and β as Immune Regulators—A New Look , 2001 .
[4] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[5] K. Kinzler,et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.
[6] H. Strander,et al. Interferons and the tumor cell , 1996, Biotherapy.
[7] M. Kastan,et al. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.
[8] H. Eguchi,et al. Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of α‐interferon and oral tegafur/uracil , 2000, Journal of gastroenterology and hepatology.
[9] T. Taniguchi,et al. Essential and non‐redundant roles of p48 (ISGF3γ) and IRF‐1 in both type I and type II interferon responses, as revealed by gene targeting studies , 1996, Genes to cells : devoted to molecular & cellular mechanisms.
[10] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[11] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[12] F. Belardelli,et al. Endogenous type I interferons as a defense against tumors. , 2002, Cytokine & growth factor reviews.
[13] T. Yagi,et al. Enhanced proliferative potential in culture of cells from p53-deficient mice. , 1993, Oncogene.
[14] D. Levy,et al. ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. , 1996, Cytokine & growth factor reviews.
[15] Michael G. Katze,et al. Viruses and interferon: a fight for supremacy , 2002, Nature Reviews Immunology.
[16] T. Taniguchi,et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 , 1994, Cell.
[17] M. Scheffner,et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.
[18] R. Metcalf,et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. , 1993, Carcinogenesis.
[19] J. D. Weber,et al. The ARF/p53 pathway. , 2000, Current opinion in genetics & development.
[20] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[21] Yoichi Taya,et al. DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.
[22] Y Taya,et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.
[23] T. Taniguchi,et al. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. , 2000, Science.
[24] D. Boothman,et al. Delayed apoptotic responses associated with radiation-induced neoplastic transformation of human hybrid cells. , 1999, Cancer research.
[25] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[26] P. Leder,et al. Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. , 1997, Cancer research.
[27] K C Zoon,et al. Interferons and their actions. , 1987, Annual review of biochemistry.
[28] R. Weinberg,et al. Cell-cycle control and its watchman , 1996, Nature.
[29] E. Baxter,et al. p53 and tumour viruses: catching the guardian off-guard. , 1997, Trends in microbiology.
[30] D. Levy,et al. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. , 2001, Cytokine & growth factor reviews.
[31] J U Gutterman,et al. Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[32] T. Taniguchi,et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.
[33] S. Wadler,et al. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. , 1990, Cancer research.
[34] C. Prives,et al. The p53 pathway , 1999, The Journal of pathology.
[35] B. Williams,et al. Identification and characterization of an interferon (IFN)-stimulated response element-IFN-stimulated gene factor 3-independent signaling pathway for IFN-α , 1994 .
[36] M. Oren. Relationship of p53 to the control of apoptotic cell death. , 1994, Seminars in cancer biology.
[37] J. Darnell,et al. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.
[38] E. Demaeyer,et al. Interferons and other regulatory cytokines , 1988 .
[39] Y Taya,et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. , 1998, Science.
[40] S Pestka,et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. , 1998, Cancer research.
[41] S. Goodbourn,et al. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. , 2000, The Journal of general virology.
[42] T. Taniguchi,et al. Distinct and Essential Roles of Transcription Factors IRF-3 and IRF-7 in Response to Viruses for IFN-α/β Gene Induction , 2000 .
[43] F. Hoppe-Seyler,et al. Functional p53 protein in human papillomavirus-positive cancer cells. , 1995, Oncogene.
[44] H. Hausen. Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.
[45] G. Evan,et al. A matter of life and cell death. , 1998, Science.
[46] J. Piette,et al. Protein-binding elements in the promoter region of the mouse p53 gene. , 1990, Oncogene.
[47] T. Veldman,et al. Transcriptional Activation of the Telomerase hTERT Gene by Human Papillomavirus Type 16 E6 Oncoprotein , 2001, Journal of Virology.
[48] Robert C. Wolpert,et al. A Review of the , 1985 .
[49] T. Taniguchi,et al. Delimitation and properties of DNA sequence: required for the regulated expression of human interferon-β gene , 1985, Cell.
[50] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.